2 models fit OptimizeRx Corporation Common Stock and they agree: 2 of 2 land within 15% of the average. The price is below every model.
Two or more of our models back this value.
Near fair value(i)Bronze57
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionOptimizeRx Corporation Common Stock (OPRX)
Fair value (2 models)
$9.46
ACCE price target
$8.40
Rating
Fairly valued
Horizon
12 months
Fair value published on 21 Oct 2026, 13:04 CEST; previously $10.13 since 17 Oct 2026, 00:00 CEST.
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Rating published on 21 Oct 2026, 13:04 CEST.
Price used: $9.15 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
3.3% below
+3.4% to fair value
ACCE score
51
out of 100
Analysts
100% buy
6 covering
P/E
38.1x
forward 5.7x
1-year return
-53.3%
Dividend yield
0.00%
OptimizeRx Corporation Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
OptimizeRx sells digital health messaging and point-of-care engagement software that puts pharma brand content and patient reminders into physician workflows and pharmacy channels, and its gross margin of 73.2% reflects a software-like revenue base. Revenue has fallen 29.8%, so the core question is whether the platform can stabilize and return to growth before cash generation and the thin 3.7% ROE are tested further. The trailing P/E of 35.4 sits against a forward P/E of 5.6, a gap that signals the market expects earnings to rebound sharply from a depressed base, which makes the forecast the thing to verify. Operating margin is roughly breakeven at -0.4%, so any recovery in pharma marketing budgets should flow through meaningfully to profit. At a $160M market cap with no index membership, the name is small, under-followed, and cheap to research, which is reason enough to look harder at the revenue bridge and the consensus earnings assumptions.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Revenue falling sharply
Revenue is down 29.8% year over year and earnings down 66.8%. Operating margin is slightly negative at -0.4%, so the business is not currently covering its operating costs.
moderate
Thin profitability despite gross margin
A 73.2% gross margin is undercut by a -0.4% operating margin and ROE of just 3.7%. Net margin of 4.7% looks flattered relative to operations.
moderate
Elevated short interest
Short interest stands at 6.2% of float alongside a sharp revenue decline, suggesting some investors expect the drop to persist.
AI research notes
AI-assisted·How I use AIWritten Oct 16, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Free cash flow over the last 12 months reached $19M, and the stock trades at a free cash flow yield of 11.9%.
Analysts' mean price target of $12.60 sits 42.4% above the share price, and all six covering analysts rate it Buy or Strong Buy.
The latest quarter's earnings per share beat expectations by 700.0%, coming in at 0.08 against 0.01 expected.
Why it could disappoint
Revenue fell 29.8% year over year, far below the 20.4% annual average growth it posted over five years.
Return on invested capital is just 2.7% and return on equity 3.7%, so the business earns little on the money put into it.
The diluted share count rose 3.9% last fiscal year, diluting existing shareholders' stake in the company.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where OPRX's valuation models land
Price
$9.15
Model fair value
$9.46
Model range
$9.42 to $9.54
Fair value $9.46
Price $9.15
The price is below the whole model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores